NCT01198327View on ClinicalTrials.gov

Extended Follow-up of Patients With Macular Edema Due to Retinal Vein Occlusion

PHASE3CompletedINTERVENTIONAL
Enrollment

66

Participants

Timeline

Start Date

August 31, 2010

Primary Completion Date

December 31, 2012

Study Completion Date

December 31, 2012

Conditions
Retinal Vein Occlusion
Interventions
DRUG

ranibizumab

Intravitreal ranibizumab, .5mg dose, PRN but not less than 21 days apart.

OTHER

Peripheral Laser

Areas of nonperfusion identified on wide field angiograms will receive laser, if the patient is continuing to require ranibizumab injections.

Trial Locations (6)

30909

Southeast Retina, Augusta

77030

Retina Consultants of Houston, Houston

90211

Retina-Vitreous Associates Medical Group, Beverly Hills

95819

Retinal Consultants Medical Group, Sacremento

02114-2587

Ophthalmic consultants of Boston, Boston

07666

Retina Associates of New Jersey, Teaneck

Sponsors

Collaborators (1)

Genentech, Inc.
All Listed Sponsors
collaborator

The Macula Foundation, Inc.

OTHER

collaborator

Genentech, Inc.

INDUSTRY

lead

Peter A Campochiaro, MD

OTHER